Business Description
Compare
Compare
Traded in other countries / regions
0VY.GermanyIMAB.USA Description
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in late 2023 or early 2024. Core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 37.77 | |||||
Equity-to-Asset | 0.81 | |||||
Debt-to-Equity | 0.03 | |||||
Debt-to-EBITDA | -0.05 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 0.52 | |||||
Beneish M-Score | 2.25 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.3 | |||||
3-Year EBITDA Growth Rate | -56.1 | |||||
3-Year EPS without NRI Growth Rate | -32.8 | |||||
3-Year FCF Growth Rate | -29.1 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 63.07 | |||||
9-Day RSI | 64.05 | |||||
14-Day RSI | 64.67 | |||||
6-1 Month Momentum % | -69.53 | |||||
12-1 Month Momentum % | -84.39 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 7.31 | |||||
Quick Ratio | 7.31 | |||||
Cash Ratio | 6.65 | |||||
Days Inventory | 137.42 | |||||
Days Sales Outstanding | 51.23 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.5 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 39.5 | |||||
Operating Margin % | -1511.82 | |||||
Net Margin % | -1882.31 | |||||
ROE % | -48.96 | |||||
ROA % | -41.06 | |||||
ROIC % | -218.68 | |||||
ROC (Joel Greenblatt) % | -1653.2 | |||||
ROCE % | -42.42 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 29.06 | |||||
PB Ratio | 0.94 | |||||
Price-to-Tangible-Book | 1.01 | |||||
EV-to-EBIT | -0.01 | |||||
EV-to-Forward-EBIT | -0.01 | |||||
EV-to-EBITDA | -0.01 | |||||
EV-to-Forward-EBITDA | -0.01 | |||||
EV-to-Revenue | 0.12 | |||||
EV-to-Forward-Revenue | 0.23 | |||||
EV-to-FCF | -0.01 | |||||
Price-to-Net-Current-Asset-Value | 1.13 | |||||
Price-to-Net-Cash | 1.28 | |||||
Earnings Yield (Greenblatt) % | -10000 |